EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A2A/A2B Receptor Antagonist for Cancer Immunotherapy

Hongyue Liu, Xinyu Yang, Jingyi Xu, Yuefei Wang iD, Zichen Zhao, Ke Quan, Aoqi Gao, Yang Wang, Jingbo Wu, Fei Li, Zhaoyu Zhang, Yuanyuan Ma und 9 weitere

ACS Central Science · 25.03.2026 · 12 (3) · 358-374

DOI: 10.1021/acscentsci.5c01843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Central Science, online erschienen am 13.03.2026. Verfasst von Hongyue Liu und 20 weiteren Autor:innen. Beteiligte Einrichtung: iHuman Institute, ShanghaiTech University, Shanghai 201210, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China, Tianjin Municipal Science and Technology Committee.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medicinal herbs contain natural products (NPs) possessing rich scaffolds valuable for drug discovery, particularly in oncology. While most NP-derived cancer therapeutics directly kill tumor cells, emerging opportunities lie in modulating antitumor immunity. However, target-annotated NPs for cancer immunotherapy remain scarce. Herein we established a multiplexed platform combining virtual screening, affinity selection-mass spectrometry, and metabolomics profiling to identify bioactive NPs targeting the adenosine 2A receptor (A2AR), a master regulator of tumor immunosuppression. Screening the crude extract of a medicinal herb and isolating the active constituent resulted in the discovery of a novel dual antagonist for A2AR/A2BR with preferential activity on A2AR. This compound, ER-15, adopts a unique binding mode as revealed by structural modeling, MD simulations, mutagenesis, and SAR analysis. Functionally, ER-15 reversed adenosine-mediated immunosuppression and augmented the immune checkpoint inhibitor therapy in both the animal model and patient-derived tumor organoids, supporting its therapeutic potential in anti-PD-1-resistant tumors. Therefore, our strategy is expected to overcome traditional NP discovery bottlenecks, enabling efficient identification of target-annotated novel leads for drug development.

Autor:innen und Institutionen

  • iHuman Institute, ShanghaiTech University, Shanghai 201210, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
  • Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
  • Department of Urology and Department of Pathology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 201100, China.

ORCID-Profile: Yuefei Wang, Weiqiang Lu, Wenqing Shui

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China
  • Tianjin Municipal Science and Technology Committee
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Key Laboratory of Cancer Prevention and Intervention, Zhejiang University
  • Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine, ShanghaiTech University

Zitieren

APA

Liu, H., Yang, X., Xu, J., Wang, Y., Zhao, Z., Quan, K., Gao, A., Wang, Y., Wu, J., Li, F., Zhang, Z., Ma, Y., Weng, Y., Chen, Y., Sun, L., Song, G., Shan, Y., Chai, X., Zhang, B., …, & Shui, W. (2026). Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A2A/A2B Receptor Antagonist for Cancer Immunotherapy. ACS Central Science, 12(3), 358-374. https://doi.org/10.1021/acscentsci.5c01843

Vancouver

Liu H, Yang X, Xu J, Wang Y, Zhao Z, Quan K, et al. Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A2A/A2B Receptor Antagonist for Cancer Immunotherapy. ACS Central Science. 2026;12(3):358-374. doi:10.1021/acscentsci.5c01843

BibTeX
@article{Liu2026,
  author = {Liu, Hongyue and Yang, Xinyu and Xu, Jingyi and Wang, Yuefei and Zhao, Zichen and Quan, Ke and Gao, Aoqi and Wang, Yang and Wu, Jingbo and Li, Fei and Zhang, Zhaoyu and Ma, Yuanyuan and Weng, Yuan and Chen, Ying and Sun, Liping and Song, Gaojie and Shan, Yibing and Chai, Xin and Zhang, Bingjie and Lu, Weiqiang and Shui, Wenqing},
  title = {Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A2A/A2B Receptor Antagonist for Cancer Immunotherapy},
  journal = {ACS Central Science},
  year = {2026},
  volume = {12},
  number = {3},
  pages = {358--374},
  doi = {10.1021/acscentsci.5c01843}
}
Kostenlos starten →